

February 24, 2023

**BSE Limited** 

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531 The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 Scrip code: STAR

Dear Madam/Sir,

**Sub:** Press Release

Please find attached Press Release issued by the Company titled:

"Strides flagship facility in Bangalore receives USFDA inspection closure"

Thanks & Regards,
For Strides Pharma Science Limited,

Manjula Ramamurthy Company Secretary

Encl. As above



# Strides flagship facility in Bangalore receives USFDA inspection closure

**Bangalore, India, February 24, 2023** - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR, Strides or Company) informed that the U.S. Food and Drug Administration (USFDA) today issued an Establishment Inspection Report (EIR) in relation to the inspection of the Company's flagship facility in Bangalore, India.

The Company's flagship facility was inspected by the USFDA between December 5 and 9, 2022, and a form 483 listing three inspectional observations was issued. Based on the Company's response to the observations and subsequent commitments, the USFDA has classified the outcome of this inspection as VAI (voluntary action indicated), and the EIR states that the inspection is closed.

The flagship facility in Bangalore is the largest manufacturing facility for the company, with the capability to produce finished dosage formulation products across multiple dosage formats, including tablets, capsules, ointments, creams, and liquids. The facility services the key regulated markets of the US, Europe, and Australia.

#### **About Strides**

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at www.strides.com.

#### For further information, please contact:

C	۲r	10		c
9	ш	IU	C	2

### **Badree Komandur**

Executive Director – Finance & Group CFO

+91 80 6784 0747

## **Investor Relations:**

Sandeep Baid: +91 80 6784 0791

Email: <a href="mailto:sandeep.baid@strides.com">sandeep.baid@strides.com</a>

#### **Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi

Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,

Bengaluru - 560076

### **Corporate Communication**

Pallavi Panchmatia: +91 80 6784 0193

Email: pallavi.panchmatia@strides.com

## **PR Consultancy**

Fortuna PR

K Srinivas Reddy: +91 90005 27213

srinivas@fortunapr.com

Boni Mukherjee: +91 96186 82208

boni@fortunapr.com